摘要
[目的]探讨布地奈德联合沙美特罗治疗儿童中重度哮喘的临床疗效。[方法]选取本院救治的126例中重度哮喘儿童，随机分为治疗组和对照组，每组各63例，治疗组采用布地奈德联合沙美特罗治疗，对照组仅给予布地奈德治疗，比较两组患儿连续治疗一年后第一秒用力呼气容积（FEV1）、呼气峰流速（PEF）以及白天、夜间症状评分。[结果]对照组和治疗组患儿PEF、FEV1、白天和夜间症状评分结果连续治疗一年后比治疗前均有显著改善（P〈0．05），且治疗组显著优于对照组，两组相比较差异有显著性（P〈0．05）。[结论]布地奈德联合沙美特罗治疗儿童中重度哮喘疗效显著，值得临床推广应用。
[Objective] To explore the clinical efficacy of budesonide combined salmeterol for the treatment of children with moderate to severe asthma. [Methods] Totally 126 patients with moderate to severe asthma in our hospital from Jan. 2011 to March 2012 were selected and randomly divided into treatment group（ n = 63） and control group（ n = 63）. The treatment group was given budesonide combined salmeterol, while the control group was only given budesonide. Forced expiratory volume in 1 second（FEV1）, peak expiratory flow（PEF）, daytime and night symptom scores a year after continuous treatment were compared between two groups. Kresults] Compared with before treatment, FEV1, PEF, daytime and night symptom scores in control group and treatment group were significantly improved a year after continuous treatment（ P〈0.05）. The efficacy in treatment group was significantly better than that in control group, and there was significantly difference between two groups（ P〈0.05）. [Conelusion]Budesonide combined salmeterol for the treatment of children with moderate to severe asthma has significant efficacy, so it is worthy of clinical promotion. [Key words] asthma/DT; budesonide/AD; adrenergie beta-agonists/AD
出处
《医学临床研究》
CAS
2012年第12期2328-2329,共2页
Journal of Clinical Research
